Figure 4
From: Poly(p-phenylenevinylene) nanoparticles modified with antiEGFRvIII for specific glioblastoma therapy
The cell viability of (a) EGFRvIII overexpressed LN229 and (b) EGFRvIII negative LN229 incubated with PPVN and PPVN-A at the concentration of 5 μg/mL respectively in the absence and presence of white light. ****p < 0.0001.
